New Global Guidelines Advise Against Obesity Drugs for Young Children

New global guidelines have been released, advising that children under the age of ten should not be given obesity drugs or weight-loss injections. According to BBC Health, these new recommendations suggest that medical treatments, such as GLP-1 injections like Mounjaro and Wegovy, are not appropriate for very young children. Instead, health experts emphasize that care for this age group should focus on healthy eating habits and regular physical exercise.

This update follows previous reports on the growing concern regarding childhood obesity. As noted by BBC Health, the number of children aged five to nine who are obese has increased four times since 1990, rising from 2% to 8%. Currently, estimates suggest that 170 million children and adolescents worldwide are obese, with 70 million of those falling into the five-to-nine age range. Additionally, 35 million children under the age of five are considered overweight. These conditions can lead to a higher risk of developing various diseases, including type 2 diabetes.

While some medications are approved for older adolescents, their use in younger children remains a subject of debate. BBC Health reports that some doctors have been prescribing these drugs 'off-label'—meaning they are used in ways not officially approved—and some companies are currently testing these drugs on children as young as six. However, the new guidance from health officials provides a strong recommendation against using these medicines, as well as bariatric surgery or weight-management devices, for anyone under ten.

Dr. Luz De Rigil, a director at the health organization, stated that these medical interventions might be considered for older children and adolescents only after lifestyle approaches have failed. She added that it is essential for the individual to be both 'mentally and physically prepared' for such treatments. The organization acknowledges that this is a changing field and promises to continue reviewing new evidence as it becomes available.

One of the primary concerns for experts is the long-term impact of starting such treatments at a very young age. Laurence Grummer-Strawn, a lead official in nutrition and food safety, questioned how long these treatments would last once they are started. He noted that there is currently no clear evidence showing that these drugs can be used as a temporary solution before switching to a healthy diet later in life. Because of this, officials are being very careful about using these medications without more research.

In addition to diet and exercise, the new guidelines suggest that certain types of technology might be helpful. According to BBC Health, digital tools like activity trackers and online games that encourage children to move more could be useful, although the evidence supporting these methods is still limited. The focus remains on creating sustainable, healthy habits rather than relying on medical interventions that have not been fully proven for this specific age group.

Ultimately, the message from health experts is one of caution. While the rise in childhood obesity is a serious problem that requires attention, the medical community is not yet ready to support the use of weight-loss drugs for the youngest patients. By prioritizing lifestyle changes and continuing to study the long-term effects of medical treatments, experts hope to find the safest and most effective ways to support the health of children worldwide.